Page last updated: 2024-11-13

gs-5806

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

presatovir: a respiratory syncytial virus entry inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID58029842
CHEMBL ID3410450
SCHEMBL ID2738142
MeSH IDM000597512

Synonyms (34)

Synonym
presatovir [inn]
presatovir [usan]
methanesulfonamide, n-(2-(((2s)-2-(5-((3s)-3-amino-1-pyrrolidinyl)-6-methylpyrazolo(1,5-a)pyrimidin-2-yl)-1-piperidinyl)carbonyl)-4-chlorophenyl)-
presatovir [who-dd]
gs-5806 ,
1353625-73-6
presatovir
9628AJ27JA ,
gs5806
presatovir [usan:inn]
n-(2-(((2s)-2-(5-((3s)-3-amino-1-pyrrolidinyl)-6-methylpyrazolo(1,5-a)pyrimidin-2-yl)-1-piperidinyl)carbonyl)-4-chlorophenyl)-methanesulfonamide
gs 5806
unii-9628aj27ja
CS-4596
SCHEMBL2738142
HY-16727
CHEMBL3410450
AKOS030526442
n-{2-[(2s)-2-{5-[(3s)-3-aminopyrrolidin-1-yl]-6-methylpyrazolo[1,5-a]pyrimidin-2-yl}piperidine-1-carbonyl]-4-chlorophenyl}methanesulfonamide
DB12165
n-[2-[(2s)-2-[5-[(3s)-3-aminopyrrolidin-1-yl]-6-methylpyrazolo[1,5-a]pyrimidin-2-yl]piperidine-1-carbonyl]-4-chlorophenyl]methanesulfonamide
presatovir (usan/inn)
D11216
EX-A4885
n-(2-((s)-2-(5-((s)-3-aminopyrrolidin-1-yl)-6-methylpyrazolo[1,5-a]pyrimidin-2-yl)piperidine-1-carbonyl)-4-chlorophenyl)methanesulfonamide
gs-5806gs-5806
Q27271846
C72410
AS-56181
NCGC00522116-02
bdbm50541849
DTXSID201028097
EN300-18084201
AC-36927

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"GS-5806 is a novel, orally bioavailable RSV fusion inhibitor discovered following a lead optimization campaign on a screening hit."( Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
Babaoglu, K; Boojamra, C; Carey, A; Cihlar, T; Desai, M; Eisenberg, E; Gilbert, BE; Hayes, J; Hui, H; Iwata, Q; Jordan, R; Kinkade, A; Lee, G; Mackman, RL; Parrish, JP; Perron, M; Piedra, PA; Samuel, D; Sangi, M; Saunders, O; Siegel, D; Sperandio, D; Stray, K; Strickley, R; Theodore, D; Yang, H; Zhang, L, 2015
)
2.09
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fusion glycoprotein F0Human respiratory syncytial virus A2EC50 (µMol)1.19301.19301.19301.1930AID1658333
Fusion glycoprotein F0 Human orthopneumovirusEC50 (µMol)0.00010.00010.01400.0280AID1658332
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
plasma membraneFusion glycoprotein F0Human respiratory syncytial virus A2
virion membraneFusion glycoprotein F0Human respiratory syncytial virus A2
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (43)

Assay IDTitleYearJournalArticle
AID1196705Drug uptake in dog lung relative to plasma level2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1196701Ratio of AUC (0 to 12 hrs) in epithelial lining fluid to AUC (0 to 12 hrs) in plasma of Sprague-Dawley rat at 1 mg/kg, iv2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1196693Terminal half life in po dosed cynomolgus monkey2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1196676Lipophilicity, log D of the compound by chromatography2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1196678Permeability from basolateral to apical side of human Caco2 cells at 10 uM by LC/MS/MS analysis2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1196699Antiviral activity against Respiratory syncytial virus clinical isolates2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1196679Percentage unbound in human plasma at 2 uM by equilibrium dialysis2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1196685Clearance in Sprague-Dawley rat at 1 mg/kg, iv administered as infusion over 30 mins2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1196683Oral bioavailability in Sprague-Dawley rat at 4 mg/kg2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1196712Antiviral activity against Respiratory syncytial virus M37 infected in healthy volunteer assessed as log10 reduction in viral load at 50 mg, po as loading dose followed by 25 mg, po on subsequent 4 days for total 5 days starting on days 2 to 5 post infect2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1196690Volume of distribution at steady state in cynomolgus monkey2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1196680Fold plasma shift, ratio of fraction unbound in culture media/buffer to fraction unbound in human plasma2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1196710Antiviral activity against Respiratory syncytial virus M37 infected in healthy volunteer assessed as reduction in log10 viral load AUC at 10 mg, po as loading dose followed by 5 mg, po on subsequent 4 days for total 5 days starting on days 2 to 5 post inf2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1196686Clearance in beagle dog at 1 mg/kg, iv administered as infusion over 30 mins2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1196698Antiviral activity against Respiratory syncytial virus type B2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1658332Inhibition of Human respiratory syncytial virus A2 Fusion protein expressed in Hep2 cells assessed as reduction in virus-induced cytopathic effect after 4 days by Celltiter-Glo viability assay2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
Discovery of a Potent Dual Inhibitor of Wild-Type and Mutant Respiratory Syncytial Virus Fusion Proteins.
AID1196677Permeability from apical to basolateral side of human Caco2 cells at 10 uM by LC/MS/MS analysis2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1196692Terminal half life in po dosed beagle dog2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1196708Antiviral activity against Respiratory syncytial virus M37 infected in healthy volunteer assessed as reduction in log10 viral load AUC at 50 mg, po as loading dose followed by 25 mg, po on subsequent 4 days for total 5 days starting on days 2 to 5 post in2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1196688Volume of distribution at steady state in Sprague-Dawley rat2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1196696Oral bioavailability in cynomolgus monkey at 4 mg/kg2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1196675Antiviral activity against Respiratory syncytial virus A2 infected in human Hep2 cells assessed as protection against virus-induced cytopathogenicity after 4 days by cell-Titer Glo assay2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1196704Drug uptake in bovine lung relative to plasma level2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1578568Antiviral activity against RSV type A infected in Hep2 cells for 3 days by TMB-ELISA method2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
State of the Art in Respiratory Syncytial Virus Drug Discovery and Development.
AID1196687Clearance in cynomolgus monkey at 1 mg/kg, iv administered as infusion over 30 mins2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1196702Drug uptake in lung tissue of Sprague-Dawley rat at 1 mg/kg, iv relative to plasma level2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1196700Ratio of AUC (0 to 12 hrs) in lung to AUC (0 to 12 hrs) in plasma of Sprague-Dawley rat at 1 mg/kg, iv2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1578567Antiviral activity against RSV type B infected in Hep2 cells for 3 days by TMB-ELISA method2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
State of the Art in Respiratory Syncytial Virus Drug Discovery and Development.
AID1196681Cytotoxicity against human Hep2 cells after 4 days by cell-Titer Glo assay2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1196709Antiviral activity against Respiratory syncytial virus M37 infected in healthy volunteer assessed as reduction in absolute viral load AUC at 50 mg, po as loading dose followed by 25 mg, po on subsequent 4 days for total 5 days starting on days 2 to 5 post2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1196689Volume of distribution at steady state in beagle dog2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1196695Oral bioavailability in beagle dog at 4 mg/kg2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1196711Antiviral activity against Respiratory syncytial virus M37 infected in healthy volunteer assessed as reduction in log10 viral load AUC compound dosed po starting on days 2 to 5 post infection for total 5 days measured up to day 12 post infection relative 2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1196697Antiviral activity against Respiratory syncytial virus type A2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1196706Antiviral activity against Respiratory syncytial virus infected in cotton rat assessed as reduction in viral RNA level in lung tissue administered ip 1 hr prior infection measured on day 4 by RT-qPCR analysis2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1196691Terminal half life in po dosed Sprague-Dawley rat2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1658333Inhibition of Human respiratory syncytial virus Fusion protein D486N mutant expressed in Hep2 cells assessed as reduction in virus-induced cytopathic effect incubated for 4 hrs followed by replacement of fresh medium containing compounds and measured afte2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
Discovery of a Potent Dual Inhibitor of Wild-Type and Mutant Respiratory Syncytial Virus Fusion Proteins.
AID1196707Antiviral activity against Respiratory syncytial virus infected in cotton rat assessed as log10 reduction in plaque forming unit equivalent in lung tissue at 0.3 to 30 mg/kg, ip administered 1 hr prior infection measured on day 4 by RT-qPCR analysis relat2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1196703Drug uptake in epithelial lining fluid of Sprague-Dawley rat at 1 mg/kg, iv relative to plasma level2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1196694Terminal half life in po dosed human2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1196682Cytotoxicity against human MT4 cells2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's8 (72.73)24.3611
2020's3 (27.27)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.07 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (36.36%)5.53%
Reviews1 (9.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (54.55%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]